Pimecrolimus
Cat. No.：YN481349
CAS No. ：137071-32-0
规格
价格(RMB)
库存
| 产品名称: | Pimecrolimus |
| CAS No.: | 137071-32-0 |
| Chemical Name: | (9E)-3S-[(1E)-2-[(1R,3R,4S)-4R-chloro-3-methoxycyclohexyl]-1-methylethenyl]-8-ethyl-5S,6,8R,11,12S,13,14S,15R,16S,17,18R,19R,24,25,26,26aS-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotric |
| Synonyms: | 吡美莫司; SDZ-ASM 981 |
| 分子量: | 810.45 |
| 分子式: | C₄₃H₆₈ClNO₁₁ |
| SMILES: | O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@@H](Cl)CC4)[C@H](C)[C@@H](O)CC3=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Pimecrolimus是免疫亲和素（immunophilin）配体，能特异地与胞质受体（immunophilin macrophilin-12）相结合。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Bochelen, D., Rudin, M., and Sauter, A.Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injuryJ. Pharmacol. Exp. Ther.288(2),653-659(1999)
Kalthoff, F.S., Chung, J., and Stuetz, A.Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cellsClin. Exp. Immunol.130,85-92(2002)
Meingassner, J.G., Kowalsky, E., Schwendinger, H., et al.Pimecrolimus does not affect Langerhans cells in murine epidermisBr. J. Dermatol.149,853-857(2003)
Kalthoff, F.S., Chung, J., Musser, P., et al.Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroidsClin. Exp. Immunol.133,350-359(2003)
Meingassner, J.G., Fahrngruber, H., and Bavandi, A.Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine AJ. Invest. Dermatol.121(1),77-80(2003)
Grassberger, M., Baumruker, T., Enz, A., et al.A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacologyBr. J. Dermatol.141,264-273(1999)
Plager, D.A., Henke, S.A., Matsuwaki, Y., et al.Pimecrolimus reduces eosinophil activation associated with calcium mobilizationInt. Arch. Allergy Immunol.149,119-126(2009)
Rappersberger, K., Komar, M., Ebelin, M.E., et al.Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well toleratedJ. Invest. Dermatol.119(4),876-887(2002)
Allen, B.R., Lakhanpaul, M., Morris, A., et al.Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patientsArch. Dis. Child.88,969-973(2003)
Walling, H.W., and Swick, B.L.Update on the management of chronic eczema: New approaches and emerging treatment optionsClin. Cosmet. Investig. Dermatol.3,99-117(2010)
